论文部分内容阅读
应用ｍｅｃＡ基因阳性的甲氧西林耐药金葡球菌２株临床分离菌株，金葡球菌９２－１０６与８９－１８７感染小鼠引起的小鼠败血症实验模型，评价抗生素８９－０７与氟氧头孢联合方案的体内抗菌活性并与去甲万古霉素单独给药进行比较。结果表明去甲万古霉素治疗金葡球菌９２－１０６和８９－１８７引起的小鼠ＭＲＳＡ感染的半数有效剂量ＥＤ５０值分别为５．８±１．１和４．１±０．８ｍｇ／ｋｇ，均显著低于抗生素８９－０７（１０．０，１０．５ｍｇ／ｋｇ）或氟氧头孢（２６；９，２９．２ｍｇ／ｋｇ）。抗生素８９－０７与氟氧头孢联合治疗ＭＲＳＡ９２－１０６与８９－１８７感染小鼠的ＥＤ５０值分别为３．８与２．５ｍｇ／ｋｇ。均显著低于去甲万古霉素、抗生素８９－０７和氟氧头孢相应的ＥＤ５０值。说明抗生素８９－０７与氟氧头孢联合方案的体内抗菌活性比去甲万古霉素强，具有统计学显著意义（Ｐ＜０．０１）。表明两药联合具有很好的体内协同作用。
The application of mecA gene-positive methicillin-resistant Staphylococcus aureus two strains of clinical isolates Staphylococcus aureus 92-106 and 89-187 mice infected mice induced sepsis model experimental evaluation of antibiotic 89-07 combined with oxyfluorocephalosporin The in vivo antibacterial activity of the regimen was compared with norvancomycin alone. The results showed that the half-effective doses of mouse MRSA infections caused by norvancomycin-treated Staphylococcus aureus 92-106 and 89-187 resulted in ED50 values of 5.8 ± 1.1 and 4.1 ± 0.8 mg / kg, respectively, Were significantly lower than antibiotics 89-07 (10.0, 10.5 mg / kg) or oxyfloxacin (26; 9, 29.2 mg / kg). The ED50 values for the combination of antibiotic 89-07 with oxyfluorocepam in mice infected with MRSA92-106 and 89-187 were 3.8 and 2.5 mg / kg, respectively. Were significantly lower than those of norvancomycin, antibiotics 89-07 and the corresponding ED50 value of oxythiosporins. The results showed that the antibacterial activity of antibiotic 89-07 in combination with fluorooxycephalosporin was significantly higher than that of norvancomycin (P <0.01). Show that the two drugs have a good synergistic effect in vivo.